AACHEN, Germany, Aug. 11, 2008 (PRIME NEWSWIRE) -- The biopharmaceutical company PAION AG (ISIN DE000A0B65S3) (Frankfurt:PA8) (London AIM:PAI) today announced its financial results according to International Financial Reporting Standards (IFRS) for the first six months ended 30 June 2008 and provides the results of the pipeline review that was conducted following the acquisition of UK-based CeNeS Pharmaceuticals. PAION will focus on selective development activities in order to maximize value creation with a balanced risk-reward profile. Based on its excellent partnering expertise and the extended pipeline with now six compounds in the clinical development stage PAION aims to build critical mass while preserving cash.
